WGS Relative Valuation
WGS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, WGS is overvalued; if below, it's undervalued.
Historical Valuation
GeneDx Holdings Corp (WGS) is now in the Overvalued zone, suggesting that its current forward PS ratio of 6.88 is considered Overvalued compared with the five-year average of 7.27. The fair price of GeneDx Holdings Corp (WGS) is between 45.81 to 78.16 according to relative valuation methord. Compared to the current price of 85.74 USD , GeneDx Holdings Corp is Overvalued By 9.7%.
Relative Value
Fair Zone
45.81-78.16
Current Price：85.74
9.7%
Overvalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
10.15
P/B
Median3y
3.30
Median5y
2.55
-0.50
FCF Yield
Median3y
-112.21
Median5y
-76.48
Competitors Valuation Multiple
The average P/S ratio for WGS's competitors is 2.12, providing a benchmark for relative valuation. GeneDx Holdings Corp Corp (WGS) exhibits a P/S ratio of 6.88, which is 225.05% above the industry average. Given its robust revenue growth of 39.56%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is GeneDx Holdings Corp (WGS) currently overvalued or undervalued?
What is GeneDx Holdings Corp (WGS) fair value?
How does WGS's valuation metrics compare to the industry average?
What is the current P/B ratio for GeneDx Holdings Corp (WGS) as of Jul 08 2025?
What is the current FCF Yield for GeneDx Holdings Corp (WGS) as of Jul 08 2025?
What is the current Forward P/E ratio for GeneDx Holdings Corp (WGS) as of Jul 08 2025?